PHILADELPHIA--(BUSINESS WIRE)--Renovacor, Inc. (NYSE: RCOR), an early-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, today announced the appointment of Jordan Shin, M.D., Ph.D., as Senior Vice President of Clinical Development and Translational Science.
“We are excited to welcome Jordan to Renovacor’s leadership team during this pivotal time for the company,” said Magdalene Cook, M.D., Chief Executive Officer of Renovacor. “Our lead program, REN-001, continues to advance towards an anticipated IND-filing in mid-2022 and earlier this month we entered the public market following the closing of our merger and concurrent financing. We believe Jordan’s nearly two decades of experience leading therapeutic candidates through the clinical trial process will be tremendously valuable as we drive forward our mission of developing novel gene therapies for diseases where there is a significant unmet medical need.”
Dr. Shin added, “It’s an honor to join Renovacor’s team of highly motivated and experienced industry experts. The company’s preclinical data set highlights REN-001 as a promising step forward towards addressing the genetic cause of BAG3-associated familial dilated cardiomyopathy, a devastating disease with no approved treatments that target the underlying cause. Renovacor’s development strategy utilizing a validated AAV9 capsid and one-time payload is based on strong foundational science, and I believe the focus on local delivery of REN-001 provides key advantages and differentiation from other genetic therapies currently in development.”
Prior to joining Renovacor, Dr. Shin served as Vice President of Medical Development at Lung Biotechnology, PBC, a subsidiary of United Therapeutics, Inc. While at Lung Biotechnology, Dr. Shin led all clinical aspects of study design and oversight, medical monitoring, site selection, and interaction and engagement for the company’s small molecule programs and oversaw FDA and international regulatory submissions for devices, small molecules and cell and gene therapies. Prior to Lung Biotechnology, he served as a consultant for Acceleron Pharma, Inc., a biopharmaceutical company developing TGF-β-targeted therapies for pulmonary and hematological diseases, and Reify Corporation, which develops advanced phenotypic drug discovery screening technologies for the biotechnology and pharmaceutical industries. Dr. Shin previously served as a board observer for Celularity, Inc., a clinical-stage biotechnology company advancing off-the-shelf, allogeneic cell therapies for cancers and degenerative diseases.
Prior to his career in industry, Dr. Shin served as a physician at Massachusetts General Hospital and an assistant professor of medicine at Harvard Medical School and specialized in the treatment of patients with advanced heart failure and heart transplant. He earned his M.D. and Ph.D. in biochemistry from the University of Alabama School of Medicine and his bachelor’s degree in applied mathematics from Harvard College.
Renovacor is a preclinical stage gene therapy company developing a pipeline of innovative and proprietary AAV-based gene therapies for BAG3 gene mutation-associated diseases in areas of high unmet medical need. Renovacor’s therapeutic focus is initially on cardiovascular disease, with a lead program in BAG3 mutation-associated dilated cardiomyopathy (DCM). For more information, please visit www.renovacor.com. No part of Renovacor’s website is incorporated by reference into or otherwise deemed to be a part of this press release.
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, as amended, including statements regarding the anticipated development of Renovacor’s product candidates. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of Renovacor’s definitive proxy statement/information statement dated August 4, 2021 and other documents filed by Renovacor from time to time with the Securities Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Renovacor assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Renovacor gives no assurance that it will achieve its expectations.